Euvichol-S口服霍乱疫苗预防尼泊尔O1群霍乱弧菌感染的安全性及免疫原性:观察者盲法、阳性对照、随机、非劣效3期试验
在尼泊尔四家医院开展的观察者盲法、阳性对照、随机、非劣效3期试验,纳入1-40岁健康人2529名,比较Euvichol-S与Shanchol。结果显示,第二剂后2周,Euvichol-S组C与Shanchol组D相比,O1群Inaba和Ogawa血清转化率差异的95%CI下限均高于-10%非劣效界值。两组不良事件发生率相近,未发现与疫苗相关的严重不良事件。
要点
- Euvichol-S两剂方案在第二剂后2周血清转化率非劣效于Shanchol。
- O1群Inaba血清转化率差异为-0.00(95%CI -1.86至1.86)。
- O1群Ogawa血清转化率差异为-1.62(95%CI -4.80至1.56)。
核心结论
- Euvichol-S两剂方案在第二剂后2周血清转化率方面非劣效于阳性对照疫苗Shanchol。
- Euvichol-S简化配方和生产要求有潜力增加口服霍乱疫苗供应并缩小供需缺口。
研究设计与样本
- 在尼泊尔四家医院开展的观察者盲法、阳性对照、随机、非劣效3期试验。
- 纳入1-40岁无霍乱疫苗接种史的健康人,排除对其它预防疫苗有过敏反应史、严重慢性病、既往霍乱疫苗接种、入组前3个月内接受血液或血制品或4周内接种其它疫苗者及孕妇哺乳期妇女。
- 采用区组随机(区组大小2、4、6或8)按1:1:1:1将参与者分配至A-D四组;C组和D组按年龄(1-5、6-17、18-40岁)分层。
- A-C组接种两剂1.5 mL Euvichol-S(三个不同批次),D组接种阳性对照疫苗Shanchol。
- 主要免疫原性终点在符合方案分析集中评估,主要安全性终点在至少接种一剂疫苗的全部参与者中评估。
主要发现
- 2021年10月6日至2022年1月19日,2529名健康参与者(男性1261名[49.9%],女性1268名[50.1%])被随机分配至A组(n=330;Euvichol-S批号ES-2002)、B组(n=331;Euvichol-S ES-2003)、C组(n=934;Euvichol-S ES-2004)或D组(n=934;Shanchol)。
- 第二剂后2周,Euvichol-S组C与Shanchol组D相比,O1群Inaba血清转化率差异为-0.00(95%CI -1.86至1.86),O1群Ogawa血清转化率差异为-1.62(95%CI -4.80至1.56),两血清型差异的95%CI下限均高于-10%非劣效界值。
- 安全性分析集2529名参与者中,244名(9.7%)报告治疗中出现的不良事件,共403起事件;Euvichol-S接种者1595名中151名(9.5%)报告247起事件,Shanchol接种者934名中93名(10.0%)报告156起事件。
- 发热是两组最常见的不良事件:Euvichol-S接种者1595名中56名(3.5%)报告57起事件,Shanchol接种者934名中35名(3.7%)报告37起事件。
- 未发现与疫苗相关的严重不良事件。
关键数值与推荐
- 非劣效界值预设为-10%:Euvichol-S组C与Shanchol组D血清转化率差异的95%CI下限高于-10%即判定为非劣效。
- 血清转化定义为与基线相比O1群Inaba和Ogawa滴度≥4倍升高。
- 主要免疫原性终点在符合方案分析集中评估,该分析集包括接受全部计划疫苗接种、无重要方案偏离且提供所有免疫原性评估血样的参与者。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In October, 2017, WHO launched a strategy to eliminate cholera by 2030. A primary challenge in meeting this goal is the limited global supply capacity of oral cholera vaccine and the worsening of cholera outbreaks since 2021. To help address the current shortage of oral cholera vaccine, a WHO prequalified oral cholera vaccine, Euvichol-Plus was reformulated by reducing the number of components and inactivation methods. We aimed to evaluate the immunogenicity and safety of Euvichol-S (EuBiologics, Seoul, South Korea) compared with an active control vaccine, Shanchol (Sanofi Healthcare India, Telangana, India) in participants of various ages in Nepal. METHODS: We did an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial at four hospitals in Nepal. Eligible participants were healthy individuals aged 1-40 years without a history of cholera vaccination. Individuals with a history of hypersensitivity reactions to other preventive vaccines, severe chronic disease, previous cholera vaccination, receipt of blood or blood-derived products in the past 3 months or other vaccine within 4 weeks before enrolment, and pregnant or lactating women were excluded. Participants were randomly assigned (1:1:1:1) by block randomisation (block sizes of two, four, six, or eight) to one of four groups (groups A-D); groups C and D were stratified by age (1-5, 6-17, and 18-40 years). Participants in groups A-C were assigned to receive two 1·5 mL doses of Euvichol-S (three different lots) and participants in group D were assigned to receive the active control vaccine, Shanchol. All participants and site staff (with the exception of those who prepared and administered the study vaccines) were masked to group assignment. The primary immunogenicity endpoint was non-inferiority of immunogenicity of Euvichol-S (group C) versus Shanchol (group D) at 2 weeks after the second vaccine dose, measured by the seroconversion rate, defined as the proportion of participants who had achieved seroconversion (defined as ≥four-fold increase in V cholerae O1 Inaba and Ogawa titres compared with baseline). The primary immunogenicity endpoint was assessed in the per-protocol analysis set, which included all participants who received all their planned vaccine administrations, had no important protocol deviations, and who provided blood samples for all immunogenicity assessments. The primary safety endpoint was the number of solicited adverse events, unsolicited adverse events, and serious adverse events after each vaccine dose in all ages and each age stratum, assessed in all participants who received at least one dose of the Euvichol-S or Shanchol. Non-inferiority of Euvichol-S compared with Shanchol was shown if the lower limit of the 95% CI for the difference between the seroconversion rates in Euvichol-S group C versus Shanchol group D was above the predefined non-inferiority margin of -10%. The trial was registered at ClinicalTrials.gov, NCT04760236. FINDINGS: Between Oct 6, 2021, and Jan 19, 2022, 2529 healthy participants (1261 [49·9%] males; 1268 [50·1%] females), were randomly assigned to group A (n=330; Euvichol-S lot number ES-2002), group B (n=331; Euvichol-S ES-2003), group C (n=934; Euvichol-S ES-2004]), or group D (n=934; Shanchol). Non-inferiority of Euvichol-S versus Shanchol in seroconversion rate for both serotypes at 2 weeks after the second dose was confirmed in all ages (difference in seroconversion rate for V cholerae O1 Inaba -0·00 [95% CI -1·86 to 1·86]; for V cholerae O1 Ogawa -1·62 [-4·80 to 1·56]). Treatment-emergent adverse events were reported in 244 (9·7%) of 2529 participants in the safety analysis set, with a total of 403 events; 247 events were reported among 151 (9·5%) of 1595 Euvichol-S recipients and 156 events among 93 (10·0%) of 934 Shanchol recipients. Pyrexia was the most common adverse event in both groups (57 events among 56 [3·5%] of 1595 Euvichol-S recipients and 37 events among 35 [3·7%] of 934 Shanchol recipients). No serious adverse events were deemed to be vaccine-related. INTERPRETATION: A two-dose regimen of Euvichol-S vaccine was non-inferior to the active control vaccine, Shanchol, in terms of seroconversion rates 2 weeks after the second dose. The simplified formulation and production requirements of the Euvichol-S vaccine have the potential to increase the supply of oral cholera vaccine and reduce the gap between the current oral cholera vaccine supply and demand. FUNDING: The Bill & Melinda Gates Foundation. TRANSLATION: For the Nepali translation of the abstract see Supplementary Materials section.
引用
- Song KR, Chapagain RH, Tamrakar D, et al. Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. Lancet Glob Health. 2024. PMID: 38614631. doi:10.1016/S2214-109X(24)00059-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。